Agendia BV Announces New Agreement With Daiichi Sankyo, Inc. To Support Oncology Drug Development
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.
Help employers find you! Check out all the jobs and post your resume.